|
Inflammatory biomarkers
|
HD start
|
End of study
|
pa
|
pb
|
|---|
|
(0 min)
|
(360 min)
|
|---|
|
P-Albumin (g/L)
|
Overall:
|
38.8 ± 2.1
|
Overall:
|
40.4 ± 2.5
|
0.12
|
< 0.001
|
|
Mean ± SD
|
NT:
|
39.5 ± 1.4
|
NT:
|
41.3 ± 2.3
| | |
| |
G:
|
38.1 ± 1.9
|
G:
|
40.4 ± 2.7
| | |
| |
GI:
|
38.6 ± 2.8
|
GI:
|
39.6 ± 2.4
| | |
|
P-Fibrinogen (μmol/L)
|
Overall:
|
11.7 ± 1.7
|
Overall:
|
12.8 ± 1.8
|
0.12
|
< 0.001
|
|
Mean ± SD
|
NT:
|
11.9 ± 1.9
|
NT:
|
13.0 ± 2.0
|
| |
G:
|
11.6 ± 1.6
|
G:
|
12.6 ± 1.6
|
|
GI:
|
11.7 ± 1.9
|
GI:
|
12.8 ± 2.0
|
|
S-hsCRP (mg/L)
|
Overall:
|
4.52 [0.40-10.68]
|
Overall:
|
4.67 [0.44-11.25]
|
0.61
|
0.55
|
|
Median [range]
|
NT:
|
4.75 [0.58-10.08]
|
NT:
|
6.06 [0.55-11.25]
|
| |
G:
|
3.21 [0.50-8.20]
|
G:
|
3.35 [0.57-7.96]
|
| |
GI:
|
6.48 [0.40-10.68]
|
GI:
|
6.40 [0.44-10.23]
|
|
P-IL-1β (ng/L)
|
Overall:
|
0.042 [0.010-0.185]
|
Overall:
|
0.039 [0.010-0.095]
|
0.68
|
0.002
|
|
Median [range]
|
NT:
|
0.042 [0.011-0.185]
|
NT:
|
0.031 [0.011-0.049]
|
| |
G:
|
0.041 [0.010-0.157]
|
G:
|
0.039 [0.010-0.095]
|
| |
GI:
|
0.043 [0.010-0.166]
|
GI:
|
0.039 [0.029-0.079]
|
|
P-IL-6 (ng/L)
|
Overall:
|
0.19 [0.04-2.33]
|
Overall:
|
0.18 [0.02-0.89]
|
0.96
|
0.25
|
|
Median [range]
|
NT:
|
0.14 [0.08-1.84]
|
NT:
|
0.19 [0.04-0.89]
|
| |
G:
|
0.21 [0.04-0.97]
|
G:
|
0.17 [0.05-0.34]
|
| |
GI:
|
0.20 [0.06-2.33]
|
GI:
|
0.30 [0.02-0.45]
|
|
P-TNF-α (ng/L)
|
Overall:
|
0.42 [0.02-9.36]
|
Overall:
|
0.29 [0.02-1.82]
|
0.76
|
0.09
|
|
Median [range]
|
NT:
|
0.27 [0.10-8.53]
|
NT:
|
0.27 [0.02-1.82]
|
| |
G:
|
0.51 [0.02-2.89]
|
G:
|
0.26 [0.03-1.75]
|
| |
GI:
|
0.36 [0.25-9.36]
|
GI:
|
0.46 [0.25-1.33]
|
- Abbreviations: HD, hemodialysis; NT, no treatment; G, glucose infusion; GI, glucose-insulin infusion; hsCRP, High-sensitivity CRP; IL-1β, interleukin-1β; IL-6, interleukin-6; TNF-α, tumor necrosis factor α.
-
ap-value for comparison of differences in the change over time between no treatment (NT), glucose infusion (G), and glucose-insulin infusion (GI) study days.
-
bp-value for comparison of overall change in biomarkers from HD start to the end of the study.
